Peptides for Women: Who the Trials Actually Enrolled
Product copy says "for women." Trial rosters say something narrower. What labels and registries show about sex, pregnancy and lactation, compound by compound.
The short version
Product copy that says a peptide is "for women" rarely describes who was actually studied. A handful of approved drugs carry FDA-reviewed pregnancy and lactation sections on their labels. Bremelanotide is approved specifically for premenopausal women. Most compounds sold as research peptides have not had a human trial that reported a sex breakdown, let alone pregnancy or lactation data.
- Only FDA-approved drugs carry a reviewed pregnancy and lactation section. No research peptide has one.
- Bremelanotide (PT-141) is the one compound here approved specifically for women. Its own label still calls pregnancy data insufficient.
- Most research peptides marketed to women have had no published human trial of any kind, in women or men.
- Oxytocin is approved for use during labour, not as the nasal "bonding" spray it is marketed as.
“Peptides for women” is a shopping category, not a clinical one. It groups a handful of genuinely approved medicines with dozens of research compounds. Those compounds have not been tested in a controlled human trial, let alone one that reported who, by sex, was enrolled.
This page sorts the site’s compound records by what the trial record, not the vendor copy, says about women, pregnancy and lactation, class by class.
For an FDA-approved drug, the label has a reviewed Pregnancy section and a Lactation section, built from the trials that won the approval. That text is the strongest, most checkable population data anywhere in this space, so it comes first, quoted from DailyMed. For everything unapproved, there is no label and usually no completed human trial to draw a population from. I say so rather than borrowing the approved-drug format for a compound that hasn’t been through that process.
Approved GLP-1 and weight-management drugs
Four of the weight drugs covered on this site are FDA-approved, so each carries a reviewed label with its own Pregnancy and Lactation sections. All four give the same core instruction: stop the drug once pregnancy is recognised, because weight loss is no benefit to a pregnant patient and animal studies showed fetal harm. They differ on lactation.
| Drug | Pregnancy | Lactation |
|---|---|---|
| Wegovy (semaglutide) | Discontinue on recognised pregnancy; embryofetal mortality and structural abnormalities in animal studies | Injection: no human milk data. Tablets: semaglutide was below the measurable limit in human milk, but the absorption enhancer SNAC was present, so breastfeeding is not recommended |
| Saxenda (liraglutide) | Discontinue on recognised pregnancy; early embryonic deaths and fetal abnormalities in rats and rabbits | No human data; present unchanged in rat milk at roughly 50% of maternal plasma levels |
| Zepbound (tirzepatide) | Discontinue on recognised pregnancy; fetal growth reductions and abnormalities in pregnant rats | Measured directly in 171 human milk samples - undetectable or low in 164 of them, equivalent to under 0.02% of the maternal dose |
| Foundayo (orforglipron) | Discontinue on recognised pregnancy; no embryofetal effects in monkeys at clinically relevant exposure, malformations in rabbits at 14 times that exposure | Not recommended for nursing women; present in rat milk at roughly three times plasma concentration |
US legal status - FDA-approved · prescription only
Semaglutide, liraglutide, tirzepatide and orforglipron are each FDA-approved as specific branded products, each with its own reviewed label. A vial sold as a 'research peptide' under one of these names carries none of this reviewed pregnancy or lactation data, because it was never through the trials that produced it.
Zepbound’s label reports an actual measured breast-milk concentration from a real sample set, not an animal proxy. That is what a completed human lactation study looks like, and it is rarer than you might expect for a drug class this widely used.
Cagrilintide, retatrutide and survodutide, the investigational compounds in the same mechanistic family, have none of this. They are not approved anywhere, so no regulator has reviewed a label, and no Pregnancy or Lactation section exists for any of them.
Their Phase 3 trials are real and large. I have not verified what those trials’ own protocols say about pregnancy exclusion or reporting. Standard practice for randomised obesity trials is to exclude pregnant and breastfeeding participants at enrolment rather than report outcomes in them, which is not the same as a reviewed label.
The one drug actually approved for women: bremelanotide
PT-141, sold as Vyleesi, is the single compound on this site whose approved indication names women specifically: premenopausal women with acquired, generalised hypoactive sexual desire disorder. Its two pivotal Phase 3 trials enrolled that population directly. That is unusual, because most of this site’s compounds were never trialled in a population defined by sex at all.
US legal status - FDA-approved · prescription only
Bremelanotide is FDA-approved as Vyleesi, specifically for premenopausal women with hypoactive sexual desire disorder. The grey-market 'PT-141' sold to men is the same molecule name attached to an unverified product outside that approval.
Even here, the label is not a blanket reassurance. Its Pregnancy section states that the pregnancies recorded during the clinical trials were too few to determine whether the drug carries its own risk. It advises women to use effective contraception while taking it and to stop if pregnancy is suspected.
Being the one compound trialled in women does not mean pregnancy was tested. HSDD trials recruit women who are not trying to conceive, so pregnancy exposure data comes only from the small number of unplanned pregnancies that occurred anyway.
Perimenopause and menopause: marketed heavily, approved for neither
“Peptides for perimenopause” and “peptides for menopause” are common framings in this space, and peptides are often marketed alongside hormone therapy as if they belonged to the same category. They do not. Menopausal hormone therapy replaces oestrogen and progesterone, actual hormones, under its own FDA-reviewed labels.
None of the compounds covered on this site, approved or unapproved, carries an indication for perimenopausal or menopausal symptoms. The approved drugs here are indicated for weight management, HIV-associated visceral fat, hypoactive sexual desire disorder, or labour and postpartum bleeding. None of their labels mentions menopause. A peptide marketed near menopause content has not necessarily been trialled in a menopausal population.
Oxytocin: approved for pregnancy, not for the spray sold as “for women”
Oxytocin is the peptide on this site with the deepest history of use in women. It is an approved obstetric drug, injected to induce or augment labour and to control bleeding after delivery. Its label is explicit that this is a medical indication, not an elective one: “Oxytocin is indicated for the medical rather than the elective induction of labor.”
That label covers intravenous and intramuscular use only and never mentions intranasal administration. The nasal sprays marketed to women (and men) for bonding, libido or anxiety are not the product the label describes. They rest on no trial the label reflects and carry none of the obstetric monitoring the approved use assumes.
On nursing mothers, the label is short and unresolved: “It is not known whether this drug is excreted in human milk.”
US legal status - FDA-approved · prescription only
Injectable oxytocin is an approved prescription medicine used in obstetrics under clinical supervision. Intranasal oxytocin sold for libido, connection or anxiety is not an approved product for that purpose.
Growth-hormone-axis peptides: approved, but not trialled as a women’s product
Two GHRH-analogue drugs on this site have been FDA-approved, and neither was developed with women’s health as the target population. That matters, because both come up in women’s-health conversations anyway.
Tesamorelin (Egrifta) is approved to reduce excess visceral fat in people with HIV-associated lipodystrophy. Its label reports the demographics of its two pivotal trials: 86% male in the first (n=412) and 84% male in the second (n=404). That reflects the HIV lipodystrophy population it was studied in.
The label states it is contraindicated in pregnant women, “because modifying visceral adipose tissue offers no benefit in pregnant women and could result in fetal harm”. It separately instructs HIV-positive mothers not to breastfeed at all, for reasons specific to HIV transmission rather than to tesamorelin itself.
US legal status - FDA-approved · prescription only
FDA-approved for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. Requires a prescriber. Grey-market vials carry the name without the approval, the quality control or the indication.
Sermorelin was approved for growth hormone deficiency in children, not for any use in adult women. It is no longer listed as an active marketed product on DailyMed, so there is no current reviewed label to quote a pregnancy or lactation section from. That gap differs from a label that addresses the question and answers it cautiously, and in some ways says more.
Neither drug was trialled toward the outcomes they are often discussed for today: “anti-aging,” sleep and body composition.
Growth hormone secretagogues sold as research chemicals: no population to report
Below the approved GHRH drugs sits a cluster of unapproved secretagogues: CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin and MK-677. They are marketed to women for the same anti-aging and body-composition claims. None has a label. None has the kind of trial that would let this page report a sex breakdown:
- CJC-1295: human pharmacokinetic data exists only for the long-acting (DAC) form. Development was discontinued at Phase 2, and no population breakdown is available in a source this site can verify.
- Ipamorelin: the one human programme, a Phase 2 trial in postoperative ileus, was discontinued for insufficient efficacy before it produced the kind of reporting a label would need.
- GHRP-2 and GHRP-6: both have an older published human literature going back decades, but neither has a source in this site’s verified registry describing who was enrolled.
- Hexarelin: human data is confined to small, old GH-stimulation pharmacology studies, not trials of any consumer use.
- MK-677: the one independently verifiable controlled human trial, in patients recovering from hip fracture, was stopped early over a possible link to heart failure, before it reached a population-reporting stage.
Healing and recovery peptides: a strong animal record, a small human one
BPC-157 is widely discussed for joint and gut healing, and the interest has a basis: its animal literature shows consistently positive healing effects across many soft-tissue injury types (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below).
Its human evidence base is small: roughly 80 people across five tiny studies. The largest is a 53-person ulcerative colitis trial that was never published beyond a meeting abstract and showed a between-group difference spanning zero. No trial reports a sex-specific result.
TB-500, its frequent stack partner, has no published human randomised trial at all. The tissue-repair literature attached to it largely studied a different, full-length protein.
Neither compound is an approved drug, so no legal or clinical pathway, and no label, addresses use in pregnancy or lactation for either one.
The exception: a skin peptide actually studied in women
GHK-Cu, the copper tripeptide sold in anti-aging serums, is unusual among the compounds on this site. Its small human studies, with 41 to 71 participants, were specifically in women and tested topical effects on fine lines, skin density and elasticity. That is a genuine, if thin, women-specific human record.
It comes with a real caveat. The three studies anchoring most consumer claims are not peer-reviewed journal articles but a conference presentation, a university report and a book chapter. The one randomised trial indexed in PubMed was negative on its objective endpoints. Small and specifically female is still not robust.
Everything else: no completed human trial, so no population to describe
The largest group of compounds marketed to women on this site were never studied in people at all, in either sex, for the use they are sold for. They include mitochondrial peptides, nootropics, immune peptides, senolytics and other fat-loss research chemicals:
| Compound | What exists in humans |
|---|---|
| 5-Amino-1MQ | No published human trial of any phase; mouse data only |
| Dihexa | Zero PubMed records under a clinical-trial or RCT type; FDA states it has no human exposure data |
| FOXO4-DRI | Zero PubMed records under a clinical-trial or RCT type; cell and rodent work only |
| Humanin | No completed human efficacy trial; human data is limited to blood-level observation, not dosing |
| IGF-1 LR3 | No controlled human trial; published work uses it as a lab reagent, not something given to people |
| KPV | FDA found no clinical study or human exposure data for KPV by any route |
| PEG-MGF | FDA states no human exposure data exists; no completed human trial of any outcome |
| Pinealon | 22 PubMed records total; none is a clinical trial or RCT |
| LL-37 | Over 2,500 records, but almost all measure a person’s own natural LL-37 as a biomarker, not dosing with synthetic LL-37 |
| MOTS-c | Human trials measure the body’s own MOTS-c response to exercise; one Phase 2 dosing trial is still recruiting and has reported nothing |
| Melanotan II | Human record is dominated by case reports of serious adverse events, not controlled trials |
| Epitalon | 142 PubMed records, one tagged as a clinical trial, none as an RCT; the headline result is in human cell lines, not people |
| DSIP (delta sleep-inducing peptide) | One 1992 randomised trial in chronic insomniacs out of 519 records; sex breakdown not available here |
| Semax / Selank | A handful of Russian-language trials from the 2000s and 2010s; not sex-stratified in anything this site can verify |
Where a trial does exist for a compound in this bucket, it is usually in a specific patient population rather than in women or men as such. SS-31, for example, has 16 randomised trials, but every one is in diagnosed mitochondrial-disease patients, never in healthy adults of any sex.
Thymosin alpha-1 has the deepest trial record of this group, including a 2025 sepsis mortality trial. But sepsis and hepatitis B trial populations are not the “immune support for women” framing it is sold under.
The pattern
Three tiers, and almost nothing sold to women sits in the first one:
- Reviewed label, pregnancy and lactation sections exist: semaglutide, liraglutide, tirzepatide, orforglipron, bremelanotide, tesamorelin, oxytocin. All are approved, and all state real limits on the label itself rather than implying them by silence.
- Real randomised human trials, no label yet: cagrilintide, retatrutide and survodutide have ongoing or completed Phase 3 programmes. Tesofensine ran a Phase 3 obesity trial in Mexico. AOD-9604’s only human trial was a smaller Phase IIb obesity study, which missed its endpoint and ended development. All are investigational or discontinued, and no regulator has reviewed a pregnancy or lactation position for any of them.
- No completed human trial that reports a population at all: most of the growth-hormone secretagogues, the healing peptides, and nearly every mitochondrial, nootropic and senolytic research chemical on this site. Sex differences can’t be answered for this tier, because no completed human trial has reported a population in anyone.
Related
- Best GLP-1 for weight loss: the approved options compared
- PT-141
- Oxytocin
- Best peptides for men, ranked by human evidence
- Are peptides safe?
- Peptide side effects
Common questions
Are any peptides approved specifically for women?
Yes, one on this site: bremelanotide, sold as Vyleesi, is FDA-approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Its own label says too few pregnancies were observed in its trials to determine drug-associated risk.
Do GLP-1 weight-loss drug labels say anything about pregnancy?
Yes. The Wegovy, Saxenda, Zepbound and Foundayo labels all tell prescribers to discontinue the drug once a pregnancy is recognised. They also state that weight loss offers no benefit to a pregnant patient. Their lactation sections differ. Foundayo is not recommended for nursing women (it reached rat milk at about three times plasma levels). Wegovy tablets are not recommended while breastfeeding because the tablet's absorption enhancer reaches human milk. Saxenda reports only rat-milk data. Zepbound reports low levels in measured human milk samples.
Is oxytocin nasal spray backed by the same trials as the approved injection?
No. The approved oxytocin label covers intravenous and intramuscular use for labour induction, augmentation and postpartum bleeding control. It never mentions intranasal use. The nasal "bonding" and "libido" sprays sold online are not the studied or approved product.
Does BPC-157 have any trial data on women?
BPC-157's only human evidence is a handful of very small studies. The largest are a 53-person ulcerative colitis trial, published only as a meeting abstract, and a 17-person retrospective chart review of knee pain. Neither is a sex-stratified efficacy trial. BPC-157 is not an approved drug, so it has no legal or clinical pathway for use in pregnancy or lactation.
Why do so many research peptides have no data on women specifically?
Because most have no controlled human trial of any kind. A sex breakdown, a pregnancy exclusion criterion and a lactation warning all come out of a completed clinical development programme. Research chemicals with only rodent or cell-culture data behind them have never reached the stage where that kind of population reporting exists.
Should females take peptides?
There is no single answer, because "peptides" spans two very different categories. A handful are FDA-approved drugs with reviewed labels a prescriber can weigh against a specific patient: semaglutide, liraglutide, tirzepatide, orforglipron, bremelanotide, tesamorelin and oxytocin. Everything else sold under the "for women" label is a research compound that has not completed a human safety trial. The data to say whether it is safe for anyone, female or male, does not exist yet.
What is the downside of taking peptides?
It depends which kind. For the approved drugs on this site, the downsides are specific and on the label. GLP-1 drugs must be stopped once pregnancy is recognised, tesamorelin requires ongoing prescriber monitoring, and bremelanotide can raise blood pressure at the time of dosing. For unapproved research-chemical peptides, the downside is uncertainty itself. No regulator checks purity or dose, and no completed trial has measured what happens in humans, so known and unknown risks cannot be separated.
What's the best peptide for women?
There is no single "best" peptide for women, because almost none of the compounds marketed that way have been tested in a trial that could support the claim. Only two on this site have an approved indication tied to women's health: bremelanotide for hypoactive sexual desire disorder, and oxytocin for labour and postpartum bleeding. Both are prescription drugs for a defined medical indication, not general-purpose "women's health" products.
Are peptides like Ozempic?
Ozempic itself is a peptide drug: its active ingredient, semaglutide, is a GLP-1 receptor agonist. But most products marketed as "peptides for women" are not GLP-1 drugs and do not work the same way. They are separate molecules, mostly unapproved, with their own (usually much earlier-stage) evidence base. Sharing the word "peptide" does not mean sharing Ozempic's regulatory review, manufacturing standard or trial record.
What peptide gets rid of belly fat?
No peptide is approved to spot-treat belly fat specifically for a general consumer. Tesamorelin (Egrifta) is the closest exception. It is FDA-approved to reduce excess visceral fat, but only in people with HIV-associated lipodystrophy, the population its trials enrolled. The GLP-1 drugs, including semaglutide and tirzepatide, reduce overall body fat (including visceral fat) as part of general weight loss, not as a targeted belly-fat effect.
Does Jennifer Aniston inject peptides?
This site does not report on what any named individual takes and cannot verify claims about a specific person's injections. Even if true, such a claim would be one person's experience, not evidence of what a peptide does. Peptides discussed in that anti-aging context are usually growth-hormone secretagogues such as CJC-1295, ipamorelin and MK-677, or unapproved compounds such as BPC-157 and GHK-Cu. None of the growth-hormone secretagogues is FDA-approved for anti-aging use. GHK-Cu's own human evidence is a handful of small studies on skin outcomes in women, not a systemic anti-aging trial.
References (8 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
- 2.WEGOVY (semaglutide) injection and tablets label, Section 8.1 Pregnancy and 8.2 Lactation - discontinue on recognised pregnancy when used for weight or cardiovascular risk; no human milk data for the injection; breastfeeding not recommended on the tablets because the absorption enhancer SNAC is present in human milk.- DailyMed, National Library of Medicinelabel
- 3.SAXENDA (liraglutide) label, Section 8.1 Pregnancy and 8.2 Lactation - early embryonic deaths and fetal abnormalities in animal studies, no human lactation data.- DailyMed, National Library of Medicinelabel
- 4.ZEPBOUND (tirzepatide) label, Section 8.1 Pregnancy and 8.2 Lactation - fetal growth reductions in animal studies, breast-milk concentration data from 171 human samples.- DailyMed, National Library of Medicinelabel
- 5.FOUNDAYO (orforglipron) label, Section 8.1 Pregnancy and 8.2 Lactation - not recommended for nursing women, present in rat milk at three times plasma concentration.- DailyMed, National Library of Medicinelabel
- 6.VYLEESI (bremelanotide) label, indication statement and Section 8.1 Pregnancy - approved for premenopausal women with HSDD; clinical-trial pregnancies too few to assess drug-associated risk.- DailyMed, National Library of Medicinelabel
- 7.EGRIFTA WR (tesamorelin) label, Section 8.1 Pregnancy, Section 8.2 Lactation and clinical trial demographics - contraindicated in pregnancy, trial population 84-86% male.- DailyMed, National Library of Medicinelabel
- 8.Oxytocin injection label, indication and Section 8.1 Pregnancy / 8.2 Nursing Mothers - approved for medically indicated labour induction and postpartum haemorrhage control, not for intranasal use.- DailyMed, National Library of Medicinelabel